Spots Global Cancer Trial Database for Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Official Title: A Phase I Study of Samarium Sm-153 Lexidronam Combined With Bortezomib for Patients With Relapsed or Refractory Multiple Myeloma

Study ID: NCT00316940

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

bortezomib

samarium Sm 153 lexidronam pentasodium

Study Description

Brief Summary: RATIONALE: Radioactive substances, such as samarium 153, may release radiation as it breaks down and kill cancer cells. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also make tumor cells more sensitive to radiation. Giving samarium 153 together with bortezomib may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of samarium 153 when given together with bortezomib in treating patients with relapsed or refractory multiple myeloma.

Detailed Description: OBJECTIVES: Primary * Assess the safety and tolerability (maximum tolerated dose and dose-limiting toxicity) of samarium Sm 153 lexidronam pentasodium and bortezomib in patients with relapsed or refractory multiple myeloma. Secondary * Determine the response rate (combined complete response, partial response, and minimal response) in patients treated with this regimen. * Determine the time to response and the time to progression of disease in patients treated with this regimen. * Determine the progression-free survival and overall survival of patients treated with this regimen. * Assess the antitumor effects of this regimen in these patients. OUTLINE: This is an open-label, dose-escalation study of samarium Sm 153 lexidronam pentasodium. Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11 and samarium Sm 153 lexidronam pentasodium IV on day 3. Treatment repeats every 8 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of samarium Sm 153 lexidronam pentasodium until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. The MTD of samarium Sm 153 lexidronam pentasodium is determined with 2 different doses of bortezomib. After completion of study treatment, patients are followed every 3 months. PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.